MetaCap

Black Diamond Therapeutics Inc. Company Profile

NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.31-0.08 (-5.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Black Diamond Therapeutics at a glance

Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Black Diamond Therapeutics is led by Dr. Mark A. Velleca M.D., Ph.D. and employs about 21 people. The company's shares have traded publicly since 2020.

At a market capitalization of $75.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001701541, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Black Diamond Therapeutics do?

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Black Diamond Therapeutics Inc.
Ticker
NASDAQ: BDTX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Employees
21
Headquarters
245 First Street, Cambridge, MA, United States
Phone
617 252 0848
IPO year
2020
Market cap
$75.28M
SEC CIK
0001701541
Latest annual report
10-K · Mar 16, 2026

Companies similar to Black Diamond Therapeutics

BDTX peer companies
CompanyPrice% ChgMarket capCompare
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs BDTX
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs BDTX
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs BDTX
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs BDTX
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs BDTX
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs BDTX
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs BDTX
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs BDTX

Related